The price-to-earnings ratio for PharmaCyte Biotech Inc (NASDAQ: PMCB) is above average at 3.05x, Company’s 36-month beta value is -0.21.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PMCB is 7.08M, and currently, short sellers hold a 0.30% ratio of that floaft. The average trading volume of PMCB on October 30, 2024 was 23.39K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PMCB) stock’s latest price update
The stock price of PharmaCyte Biotech Inc (NASDAQ: PMCB) has jumped by 7.29 compared to previous close of 1.92. Despite this, the company has seen a gain of 14.44% in its stock price over the last five trading days. businesswire.com reported 2024-05-21 that LAS VEGAS–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forw.
PMCB’s Market Performance
PharmaCyte Biotech Inc (PMCB) has experienced a 14.44% rise in stock performance for the past week, with a 3.52% rise in the past month, and a 3.52% rise in the past quarter. The volatility ratio for the week is 11.48%, and the volatility levels for the past 30 days are at 8.76% for PMCB. The simple moving average for the past 20 days is 15.76% for PMCB’s stock, with a 1.85% simple moving average for the past 200 days.
PMCB Trading at 17.66% from the 50-Day Moving Average
After a stumble in the market that brought PMCB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.16% of loss for the given period.
Volatility was left at 8.76%, however, over the last 30 days, the volatility rate increased by 11.48%, as shares surge +19.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.65% upper at present.
During the last 5 trading sessions, PMCB rose by +18.31%, which changed the moving average for the period of 200-days by -1.47% in comparison to the 20-day moving average, which settled at $1.7830. In addition, PharmaCyte Biotech Inc saw -4.63% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PMCB
The total capital return value is set at -0.09. Equity return is now at value 47.88, with 35.90 for asset returns.
Currently, EBITDA for the company is -8.52 million with net debt to EBITDA at 3.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.40.
Conclusion
In a nutshell, PharmaCyte Biotech Inc (PMCB) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
